Key Takeaways
- President Trump issued an executive order over the weekend mandating accelerated FDA evaluations of psychedelic-based mental health treatments
- AtaiBeckley stock surged 28% during premarket hours; Compass Pathways stock climbed 26%
- The directive introduces Commissioner’s National Priority Vouchers for psychedelics with “breakthrough therapy” designation, reducing approval timelines from 6–10 months to just 1–2 months
- Ibogaine, currently a Schedule I controlled substance under investigation for opioid addiction treatment, receives explicit mention in the order
- Federal funding of $50 million has been designated for ibogaine research initiatives
On Saturday, President Trump issued an executive order commanding the FDA to expedite its evaluation process for psychedelic medications. The order bears the title “Accelerating Medical Treatments for Serious Mental Illness.”
The presidential mandate encompasses therapies targeting treatment-resistant depression, post-traumatic stress disorder, and substance use disorders.
FDA Commissioner Marty Makary indicated that regulatory decisions on certain medications could arrive by this summer.
The directive dramatically compresses standard review periods from 6–10 months to 1–2 months for medications already designated as “breakthrough therapies.” This acceleration mechanism operates through Commissioner’s National Priority Vouchers.
Shares of companies developing psychedelic medicines experienced dramatic gains during Monday’s premarket session. AtaiBeckley stock jumped 28%, Compass Pathways stock rose 26%, GH Research advanced 19%, Definium Therapeutics increased 15%, Cybin gained approximately 15%, and Enveric BioSciences added 7%.
With a market capitalization near $1.5 billion, AtaiBeckley stands as one of the sector’s largest publicly traded enterprises.
Market Response to Presidential Directive
The company’s primary candidate, BPL-003, is a nasal formulation aimed at treatment-resistant depression. Phase 3 clinical trials are scheduled to commence later this quarter.
Compass Pathways, a United Kingdom-based biotechnology firm, is advancing COMP360, a synthetic psilocybin therapy. The drug is undergoing late-stage clinical evaluation for treatment-resistant depression and has secured FDA Breakthrough Therapy status.
The executive order makes explicit reference to ibogaine, a psychedelic compound extracted from an African shrub species. This substance maintains Schedule I classification under U.S. law, indicating it lacks recognized medical applications according to current federal standards.
Researchers are investigating ibogaine as a potential intervention for opioid dependence. The presidential order directs regulatory authorities to facilitate access through the Right to Try Act, legislation Trump enacted in 2018.
Cardiac toxicity associated with ibogaine has presented ongoing challenges for regulatory agencies.
Financial Commitments and Industry Expert Perspectives
President Trump announced that $50 million in federal funds will support ibogaine research programs.
Jefferies analyst Andrew Tsai characterized the order as an “official stamp of validation to the class,” emphasizing that governmental backing has materialized.
RBC analyst Brian Abrahams stated the executive action “is a substantial step towards diminishing regulatory risk” for psychedelic medications.
Health Secretary Robert F. Kennedy Jr. has vocally advocated for ibogaine as an alternative intervention for depression and related mental health disorders.
Legislators across party lines have signaled intentions to advance bills expanding psychedelic therapy accessibility.
FDA Commissioner Makary confirmed the agency stands ready to implement expedited procedures under the new presidential directive.
